Tanvex Biopharma Stock Cash Per Share
| 6541 Stock | TWD 70.30 2.20 3.23% |
Tanvex BioPharma fundamentals help investors to digest information that contributes to Tanvex BioPharma's financial success or failures. It also enables traders to predict the movement of Tanvex Stock. The fundamental analysis module provides a way to measure Tanvex BioPharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tanvex BioPharma stock.
Tanvex |
Tanvex BioPharma Company Cash Per Share Analysis
Tanvex BioPharma's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Tanvex BioPharma Cash Per Share | 5.29 X |
Most of Tanvex BioPharma's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tanvex BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Tanvex BioPharma has a Cash Per Share of 5.29 times. This is 21.61% higher than that of the Healthcare sector and 22.17% higher than that of the Biotechnology industry. The cash per share for all Taiwan stocks is 5.59% lower than that of the firm.
Tanvex Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tanvex BioPharma's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tanvex BioPharma could also be used in its relative valuation, which is a method of valuing Tanvex BioPharma by comparing valuation metrics of similar companies.Tanvex BioPharma is currently under evaluation in cash per share category among its peers.
Tanvex Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (76.42) % | |||
| Current Valuation | 14.19 B | |||
| Shares Outstanding | 352.74 M | |||
| Shares Owned By Insiders | 53.74 % | |||
| Shares Owned By Institutions | 4.30 % | |||
| Price To Book | 7.12 X | |||
| Price To Sales | 681.78 X | |||
| Revenue | 5.41 M | |||
| Gross Profit | 3.55 M | |||
| EBITDA | (1.25 B) | |||
| Net Income | (1.54 B) | |||
| Cash And Equivalents | 1.65 B | |||
| Cash Per Share | 5.29 X | |||
| Debt To Equity | 0.67 % | |||
| Current Ratio | 7.89 X | |||
| Book Value Per Share | 5.35 X | |||
| Cash Flow From Operations | (1.39 B) | |||
| Earnings Per Share | (4.35) X | |||
| Target Price | 52.4 | |||
| Number Of Employees | 23 | |||
| Beta | 0.67 | |||
| Market Capitalization | 17.11 B | |||
| Total Asset | 4.71 B | |||
| Net Asset | 4.71 B |
About Tanvex BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tanvex BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tanvex BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tanvex BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.